참고문헌
- Fleisch H. Bisphosphonates in bone disease: From the laboratory to the patient 3rd Ed. 1997.
- Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in longterm cultures of human bone marrow. J Clin Invest. 1989;83(6):1930-5. https://doi.org/10.1172/JCI114100
- Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000;15(1):2-12. https://doi.org/10.1359/jbmr.2000.15.1.2
-
Jeong HJ, Yushun T, Kim BH, Nam MY, Lee HA, Yoo YJ, Seo JT, Shin DM, Ohk SH, Lee SI. Hypertonicity Down-regulates the 1
$\alpha$ ,25(OH)2Vitamin D3-induced Osteoclastogenesis Via the Modulation of RANKL Expression in Osteoblast. Int J Oral Biol. 2005;30(1);23-30. - Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest. 1998;101(9):1942-50. https://doi.org/10.1172/JCI1039
- Kawata T, Tenjou K, Tokimasa C, Fujita T, Kaku M, Matsuki A, Kohno S, Tsutsui K, Ohtani J, Motokawa M, Shigekawa M, Tohma Y, Tanne K. Effect of alendronate on osteoclast differentiation and bone volume in transplanted bone. Exp Anim. 2004;53(1):47-51. https://doi.org/10.1538/expanim.53.47
- Kim YH, Kim GS, Jeong-Hwa B. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med. 2002; 34(2):145-51. https://doi.org/10.1038/emm.2002.21
- Klein BY, Ben-Bassat H, Breuer E, Solomon V, Golomb G. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. J Cell Biochem. 1998;68(2):186-94. https://doi.org/10.1002/(SICI)1097-4644(19980201)68:2<186::AID-JCB5>3.0.CO;2-R
- Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2):165-76. https://doi.org/10.1016/S0092-8674(00)81569-X
- Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer. 2001;84(7):951-8. https://doi.org/10.1054/bjoc.2000.1679
- Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604-10. https://doi.org/10.1056/NEJM200008313430902
- Papoulous S. Bisphosphonates: Pharmacology and use in the treatment of osteoporosis. In Osteoporosis. pp. 1209-34. 1996.
- Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res. 1996;11(2):150-9.
- Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104(10):1363-74. https://doi.org/10.1172/JCI6800
- Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000;60(21):6001-7.
- Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309-19. https://doi.org/10.1016/S0092-8674(00)80209-3
- Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12 Suppl):2961-78. https://doi.org/10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L
- Roodman GD. Advances in bone biology: the osteoclast. End Rev. 1996;17:308-22.
- Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339(5):292-9. https://doi.org/10.1056/NEJM199807303390502
- Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993;91(5):2004-11. https://doi.org/10.1172/JCI116422
- Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309-19. https://doi.org/10.1016/S0092-8674(00)80209-3
- Shin JY, Baek DH, Han SB. The Effects of Sex Hormones on the Expression of ODF/OPG in Human Gingival Fibroblast and Periodontal Ligament Cell at Serum Concentration During Pregnancy. Int J Oral Biol. 2005;30(3):105-110.
- Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res. 1997; 2(6):869-79.
- Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20(3):345-57. https://doi.org/10.1210/er.20.3.345
- Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 1996;137(6):2324-33. https://doi.org/10.1210/en.137.6.2324
- Wise GE, Lin F. The molecular biology of initiation of tooth eruption. J Dent Res. 1995; 74(1):303-6. https://doi.org/10.1177/00220345950740010301
- Wise GE, Huang H, Que BG. Gene expression of potential tooth eruption molecules in the dental follicle of the mouse. Eur J Oral Sci. 1999;107(6):482-6. https://doi.org/10.1046/j.0909-8836.1999.eos107610.x
- Wise GE, Yao S, Zhang Q, Ren Y. Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption. Arch Oral Biol. 2002a;47(3):247-54. https://doi.org/10.1016/S0003-9969(01)00109-1
- Wise GE, Frazier-Bowers S, D'Souza RN. Cellular, molecular, and genetic determinants of tooth eruption. Crit Rev Oral Biol Med. 2002b;13(4):323-34. https://doi.org/10.1177/154411130201300403
- Wise GE, Yao S. Expression of vascular endothelial growth factor in the dental follicle. Crit Rev Eukaryot Gene Expr. 2003;13(2-4):173-80. https://doi.org/10.1615/CritRevEukaryotGeneExpr.v13.i24.90
- Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998;95(7):3597-602. https://doi.org/10.1073/pnas.95.7.3597